ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.628,90
-0,70%
S&P 500
5.293,54
-0,21%
US Dollar vs BRL
5,16
-0,26%
Bitcoin
68.233,19
-1,67%
Brent Oil
84,24
1,68%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Coya Therapeutics Inc (COYA)

  7. Coya Therapeutics Inc (COYA) Notícias

COYA

Coya Therapeutics (COYA)

Coya Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:COYA
DataHoraFonteTítuloCódigoCompanhia
28/05/202409:15Business WireCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexNASDAQ:COYACoya Therapeutics Inc
22/05/202409:15Business WireCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseNASDAQ:COYACoya Therapeutics Inc
20/05/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
20/05/202409:15Business WireCoya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)NASDAQ:COYACoya Therapeutics Inc
09/05/202417:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COYACoya Therapeutics Inc
09/05/202417:10Business WireCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
26/04/202409:15Business WireCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
22/04/202409:15Business WireCoya Therapeutics to Participate in the Mizuho Neuroscience SummitNASDAQ:COYACoya Therapeutics Inc
18/04/202409:15Business WireCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:COYACoya Therapeutics Inc
08/04/202409:15Business WireCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
19/03/202409:15Business WireCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
12/03/202410:00Business WireCoya Therapeutics to Participate in BTIG Fireside DiscussionNASDAQ:COYACoya Therapeutics Inc
12/03/202409:00Business WireCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
06/03/202410:15Business WireCoya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
05/03/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
29/02/202410:15Business WireCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
22/02/202410:15Business WireCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
21/02/202410:15Business WireCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”NASDAQ:COYACoya Therapeutics Inc
13/02/202410:15Business WireCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesNASDAQ:COYACoya Therapeutics Inc
29/01/202410:15Business WireCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
18/01/202410:15Business WireCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesNASDAQ:COYACoya Therapeutics Inc
16/01/202418:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COYACoya Therapeutics Inc
16/01/202410:15Business WireCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisNASDAQ:COYACoya Therapeutics Inc
16/01/202406:06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:COYACoya Therapeutics Inc
05/01/202410:00Business WireCoya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)NASDAQ:COYACoya Therapeutics Inc
04/01/202418:46Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:COYACoya Therapeutics Inc
20/12/202311:46Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:COYACoya Therapeutics Inc
20/12/202310:30Business WireMr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.NASDAQ:COYACoya Therapeutics Inc
13/12/202310:00Business WireCoya Therapeutics’ CEO Dr. Howard Berman’s Letter to StockholdersNASDAQ:COYACoya Therapeutics Inc
12/12/202310:00Business WireCoya Therapeutics Announces Closing of $26.5 Million Private PlacementNASDAQ:COYACoya Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:COYA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
RCSL3
RECRUSUL ON
BOV
GFSA3
GAFISA ON
BOV
RCSL4
RECRUSUL PN
BOV
RPMG3
PET MANGUINH ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
HAGA3
HAGA ON
BOV
AZEV4
AZEVEDO PN
BOV
TECN3
TECHNOS ON
BOV
TRAD3
TC ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
CVCB3
CVC BRASIL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados